UNCY - Latest News
Unicycive Therapeutics, Inc. (UNCY), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $101.4M. Beta to the broader market is 1.82.
The article list below shows the most recent UNCY headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent UNCY Headlines
UNICYCIVE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
newsfilecorp.com - Oct 16, 2026
New York, New York--(Newsfile Corp. - October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of
Kaplan Fox Advises Investors of Unicycive Therapeutics, Inc. (UNCY) of an Upcoming Securities Class Action Deadline on November 2, 2026
newsfilecorp.com - Oct 15, 2026
New York, New York--(Newsfile Corp. - October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Un
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
prnewswire.com - Oct 15, 2026
Unicycive's annual report warned only that the FDA "could ask us to supplement our submissions," while a securities class action alleges the Company n
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com - Oct 15, 2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a cl
UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
newsfilecorp.com - Oct 15, 2026
New York, New York--(Newsfile Corp. - October 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of
How News Affects UNCY Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track UNCY's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked UNCY news questions
- What is the latest UNCY news headline?
- The most recent UNCY headline (Oct 16, 2026) is "UNICYCIVE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - UNCY". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the UNCY news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What UNCY news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual UNCY options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.